trending Market Intelligence /marketintelligence/en/news-insights/trending/da3andvvtaqxld_0vfecrg2 content esgSubNav
In This List

Portola Pharmaceuticals CEO to retire; interim co-presidents named

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Portola Pharmaceuticals CEO to retire; interim co-presidents named

Portola Pharmaceuticals Inc. said William Lis will retire as CEO and board member Aug. 1.

Lis, who joined the South San Francisco, Calif.-based Portola in 2008, will remain with the company in an advisory role after retirement.

The company has initiated a search to find a suitable replacement.

Executive Vice President John Curnutte and CFO Mardi Dier will serve as co-presidents in addition to their current roles on an interim basis.

Portola is a biopharmaceutical company that develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders and inflammation.